Agenus (AGEN)
8.24
0.00 (0.00%)
Upcoming Events
Latest Headlines
Agenus drug combo shows 33% three-year survival in colorectal cancer
August 28, 2026 10:07 AM - StreetInsider
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
August 28, 2026 10:07 AM - BizWire
Agenus reports no recurrences in Phase 2 colon cancer drug trial
August 26, 2026 10:05 AM - StreetInsider
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
August 26, 2026 10:05 AM - BizWire
Form 8-K AGENUS INC For: Aug 12
August 18, 2026 4:31 PM - SEC Filing
Form EFFECT AGENUS INC
August 17, 2026 6:17 AM - SEC Filing
Form 424B3 AGENUS INC
August 17, 2026 6:17 AM - SEC Filing
Form 8-K AGENUS INC For: Aug 10
August 13, 2026 6:05 AM - SEC Filing
Form 4 AGENUS INC For: Aug 10 Filed by: ARMEN GARO H
August 12, 2026 9:30 PM - SEC Filing
Form 8-K AGENUS INC For: Aug 05
August 11, 2026 4:30 PM - SEC Filing
Form 4 AGENUS INC For: Aug 05 Filed by: HARRISON THOMAS L
August 11, 2026 4:09 PM - SEC Filing
Form 4 AGENUS INC For: Aug 05 Filed by: Corvese Brian
August 11, 2026 4:07 PM - SEC Filing
Agenus Inc. (AGEN) PT Lowered to $25 at H.C. Wainwright
August 11, 2026 6:51 AM - StreetInsider
Form 10-Q AGENUS INC For: Jun 30
August 7, 2026 4:32 PM - SEC Filing
Form S-8 AGENUS INC
August 7, 2026 4:17 PM - SEC Filing
Form S-3 AGENUS INC
August 7, 2026 4:03 PM - SEC Filing
Form 4 AGENUS INC For: Aug 05 Filed by: Wright Timothy
August 7, 2026 2:34 PM - SEC Filing
Form 4 AGENUS INC For: Aug 05 Filed by: O'Day Steven J
August 7, 2026 2:30 PM - SEC Filing
Form 4 AGENUS INC For: Aug 05 Filed by: Hirsch Susan B
August 7, 2026 2:17 PM - SEC Filing
Form 4 AGENUS INC For: Aug 05 Filed by: Buell Jennifer
August 7, 2026 2:08 PM - SEC Filing
Form 8-K AGENUS INC For: Aug 06
August 6, 2026 7:53 AM - SEC Filing
Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial
August 6, 2026 7:30 AM - StreetInsider
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
August 6, 2026 7:30 AM - BizWire
Agenus Inc. (AGEN) PT Raised to $14 at B.Riley
July 30, 2026 8:47 AM - StreetInsider
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
July 28, 2026 4:30 PM - BizWire
Form EFFECT AGENUS INC
July 28, 2026 6:05 AM - SEC Filing
Form SCHEDULE 13G AGENUS INC Filed by: BlackRock, Inc.
July 27, 2026 4:26 PM - SEC Filing
Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
July 20, 2026 4:17 PM - SEC Filing
Agenus (AGEN) files for 2.13M share offering by selling stockholders
July 20, 2026 6:08 AM - StreetInsider
Form S-3 AGENUS INC
July 20, 2026 6:02 AM - SEC Filing
Form SCHEDULE 13G AGENUS INC Filed by: Invus Global Management, LLC
July 17, 2026 4:39 PM - SEC Filing
Agenus to present BOT+BAL cancer data at ESMO 2026 congress
July 17, 2026 10:28 AM - StreetInsider
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
July 17, 2026 10:28 AM - BizWire
Form 4 AGENUS INC For: Jul 10 Filed by: ARMEN GARO H
July 14, 2026 3:30 PM - SEC Filing
Agenus Inc. (AGEN) PT Raised to $30 at H.C. Wainwright
July 13, 2026 12:16 PM - StreetInsider
Agenus rises premarket; Micron, Western Digital slide
July 13, 2026 6:33 AM - StreetInsider
Form 8-K AGENUS INC For: Jul 13
July 13, 2026 6:31 AM - SEC Filing
Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial
July 13, 2026 6:00 AM - StreetInsider
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
July 13, 2026 6:00 AM - BizWire
Form 4 AGENUS INC For: Jul 01 Filed by: HARRISON THOMAS L
July 7, 2026 10:48 AM - SEC Filing
Form 4 AGENUS INC For: Jul 01 Filed by: Wright Timothy
July 7, 2026 10:42 AM - SEC Filing
Form 8-K AGENUS INC For: Jun 29
July 6, 2026 4:11 PM - SEC Filing
Agenus reports 3-year survival data for colorectal cancer drug combo
July 6, 2026 7:31 AM - StreetInsider
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
July 6, 2026 7:30 AM - BizWire
Form 4 AGENUS INC For: Jun 26 Filed by: ARMEN GARO H
June 30, 2026 6:06 AM - SEC Filing
Agenus to present 3-year colorectal cancer survival data at ESMO GI
June 25, 2026 7:00 AM - StreetInsider
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
June 25, 2026 7:00 AM - BizWire
Form 8-K AGENUS INC For: Jun 16
June 23, 2026 10:14 AM - SEC Filing
Form 4 AGENUS INC For: Jun 12 Filed by: ARMEN GARO H
June 16, 2026 9:00 AM - SEC Filing
Full Article List
